Anti-inflammatory drugs and prediction of new structures by comparative analysis

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2012, Pages 151-160

  Bartzatt, Ronald ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Analgesic; Anti inflammatory; Antipyretic; NSAID; Pattern recognition

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DROXICAM; LICOFELONE; MECLOFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; TOLFENAMIC ACID;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; CANCER RISK; CHEMICAL STRUCTURE; CLUSTER ANALYSIS; COMPARATIVE STUDY; DRUG DESIGN; DRUG DISCRIMINATION; DRUG STRUCTURE; INFLAMMATORY DISEASE; MOLECULAR MODEL; MULTIPLE REGRESSION; PHARMACODYNAMICS; PREDICTION; STATISTICAL ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR WEIGHT; REGRESSION ANALYSIS;

EID: 84870266374     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/187152312803305768     Document Type: Article

References (40)

1. Simone, R. Australian Medicines Handbook 2006, Pty Limited: Adelaide, 2006.
2. Vane, J.R.; Botting, R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
3. Vane, J.R.; Botting, R.M. Mechanism of action of anti-inflammatory drugs. Int. J. of Tissue Reactions, 1998, 20(1), 3-15.
4. Cashman, J.N. The mechanisms of action of NSAIDs in analgesia. Drugs, 1996, 52(suppl 5), 13-23.
5. Vane, J.R. Introduction: Mechanism of action of NSAIDs. Brit. J. of Theumatology, 1996, 35(suppl 1), 1-3.
6. Ulrich, C.M.; Bigler, J.; Potter, J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and phamacogenetics. Nature, 2006, 6, 130-140.
7. Thun, M.J.; Henley, S.J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. of the Nat. Canc. Inst., 2002, 94(4), 252-266.
8. Harris, R.E.; Beebe-Donk, J.; Doss, H.; Burr Doss, D. Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (review). Oncol. Rep., 2005, 13(4), 559-583.
9. Rao, C.V.; Reddy, B.S. NSAIDs and chemoprevention. Curr. Cancer Drug Targets, 2004, 4, 29-42.
10. Lev-Ari, S.; Lichtenberg, D.; Arber, N. Compositions for treatment of cancer and inflammation. Recent Pat. Anticancer Drug Discov., 2008, 3(1), 55-62.
11. Baron, J.A. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res., 2003, 37, 1-24.
12. Carlson, R.H. NSAIDs inhibit colorectal, oral cancers. Oncology Times, 2005, 27(12), 43-44.
13. Rostom, A.; Dube, C.; Lewin, G. Use of aspirin and NSAIDs to prevent colorectal cancer. An Evidence Synthesis. AHRQ Publication: Rockville, 2007.
14. Harris, R.E.; Beebe-Donk, J.; Alshafie, G.A. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase- 2-(COX-2) inhibitors. BMC Cancer, 2008, 8, 237-242.
15. Cooper, K.; Squires, H.; Carroll, C.; Papaioannou, D.; Booth, A.; Logan, R.F.; Maguire, C.; Hind, D.; Tappenden. P. Chemoprevention of colorectal cancer: Systematic review and economic evaluation. Health Technol. Assess, 2010, 14(32), 1-206.
16. Shaheen, N.J.; Straus, W.L.; Sandler, R.S. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti-inflammatory drugs. Cancer, 2002, 94(4), 950-963.
17. Wei, W.Q.; Qiao, Y.L. Non-steroidal anti-inflammatory drugs and chemoprevention of digestive cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2001, 23(1), 78-82.
18. Husain, S.S.; Szabo, I.L.; Tamawski, A.S. NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action. Am. J. Gastroenterol., 2002, 97(3), 542-553.
19. Jacobs, E.J.; Rodriguez, C.; Mondul, A.M.; Connell, C.J.; Henley, S.J.; Calle, E.E.; Thun, M.J. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl. Cancer Inst., 2005, 97(3), 975-980.
20. Daugherty, S.E.; Pfeiffer, R.M.; Sigurdson, A.J.; Hayes, R.B.; Leitzmann, M.; Schatzkin, A.; Hollenbeck, A.R.; Silverman, D.T. Nonteroidal anti-inflammatory drugs and bladder cancer: A pooled analysis. Am. J. Epidermiol., 2011, 173(7), 721-730.
21. McCormack, V.; Hung, R.; Brenner, D.; Bickeboller, H.; Rosenberger, A.; Muscat, J.; Lazarus, P.; Tjonneland, A.; Friis, S.; Christiani, D.; Chun, E.; Le Marchand, L.; Rennert, G.; Rennert, H.; Andrew, A.; Orlow, I.; Park, B.; Boffetta, P.; Duell, E. Aspirin and NSAID use and lung cancer risk: A pooled analysis in the international lung cancer consortium (ILCCO). Cancer Causes Control, 2011, 22(12), 1709-1720.
22. Lim, W.; Chauah, K.; Eng, P.; Leong, S.; Lim, E.; Lim, T.; Ng, A.; Poh, W.; Tee, A.; The, M.; Salim, A.; Seow, A. Aspirin and nonaspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. Lung Cancer, 2012, in press.
23. Hashitani, S.; Urade, M.; Nishimura, N.; Maeda, T.; Takaoka, K.; Noguchi, K.; Sakurai, K. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a sective cyclooxygenase- 2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol., 2003, 23(3), 665-672.
24. Yip-Schnieider, M.T.; Sweeney, C.J.; Jung, S.; Crowell, P.L.; Marshall, M.S. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. The J. Pharmacol. Exp. Therapeutics, 2001, 298(3), 976-985.
25. Wu, G.; Yi, J.; Di, F.; Zou, S.; Li, X. Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells. J. Huazhong Univ. Technolog. Med. Sci., 2005, 25(1), 42-44.
26. Wu, G.S.; Zou, S.; Liu, Z.; Tang, Z.; Wang, J. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J. Gastroenterol., 2003, 9(6), 1302-1306.
27. Wang, J.; Peng, Z.; Liu, X.Q.; Yang, K.; Lou, J.; Luo, F. The growth inhibitory effect of nonsteroidal anti-inflammatory drugs on ovarian cancer. Sichuan Da Xue Xue Bao Yi Xue Ban, 2007, 38(3), 428-432.
28. De Luna-Bertos, E.; Ramos-Torrecillas, J.; Garcia-Martinez, O.; Diaz-Rodriguez, L.; Ruiz, C. Effect of aspirin on cell growth of human MG-63 osteosarcoma line. Scientific World J., 2012, 834246, 1-6.
29. Anderson, N.H.; Santeau, J. Weak inference with linear models. Psychological Bull., 1977, 84, 1155-1170.
30. Lipinski, C.; Lombardo, F.; Dominy, B.; Feeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev., 1997, 23(1-3), 3-25.
31. Veber, D.; Johnson, S.; Cheng, J.; Smith, B.; Ward, K.; Kopple, K. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45, 2615-2623.
32. Testa, B.; Pliska, V.; van de Waterbeemd, H. Lipophilicity in Drug Action and Toxicology, VCH: New York, 1995.
33. Beetge, E.; du Plessis, J.; Muller, D.; Goosen, C.; van Rensburg. The influence of the physiochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. Int. J. Pharm., 2000, 193, 261-264.
34. Goosen, C.; Du Plessis, J.; Muller, D.; van Rensburg, J. Correlation between physicochemical characteristics pharmacokinetic properties and transdermal absorption of NSAID's. Int. J. Pharm., 1998, 163, 203-209.
35. van de Waterbeemd, H.; Gifford, E. ADMET in silico modeling: Toward prediction paradise. Nat. Rev. Drug Discov., 2003, 2, 192-204.
36. Kelder, J.; Grootenhuis, P.D.; Bayada, D.; Delbressine, L.; Ploemen, J. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res., 1999, 16, 1514-1519.
37. Egan, W.J.; Merz, K.M.; Baldwin, J.J. Prediction of drug absorption using multivariate statistics. J. Med. Chem., 2000, 43, 3867-3877.
38. Davis, J.C. Statistics and Data Analysis in Geology. John Wiley & Sons: New York, 1986.
39. Agatonovic-Kustrin, S.; Beresford, R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J. Pharm. Biomed. Anal., 2000, 22(5), 717-727.
40. Cohen, J.; Cohen, P.; West, S.G.; Aiken, L.S. Applied multiple regression/correlation analysis for the behavioral sciences, 3rd Ed.; Lawrence Erlbaum Associates: Mahwah, 2003.